MAP2K7 and thyroid cancer: These data motivated studies conducted with RAI-refractory thyroid cancer patients using MEK (selumetinib, trametinib, and cobimetinib) or BRAFV600E inhibitors (dabrafenib or vemurafenib), or a combination of both as a redifferentiation strategy to improve RAI avidity and induce better responses to RAI therapy [18,21,22,98,99,100,101,102].